OakChart

Exelixis Inc

EXELHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 10:36 AM ET

70.16-0.42 (-0.60%)
2026-11-11 16:36 CET
Market cap
17,222.30 USD m
Revenue, TTM
2,496.86 USD m
Net income, TTM
885.14 USD m
Free cash flow, TTM
1,161.09 USD m
EPS diluted, TTM
3.34
P/E
21.00
Compare

Price

EXEL against its 20, 50 and 200-day averages
2050200beat
40.0050.0060.0070.003.4M6.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EXELclose 70.1620-day 67.2450-day 61.85200-day 51.9770.1652w high

4.8% under the 52-week high of 73.69 on 5 Nov 2026. 52-week low 39.71 on 2 Mar 2026. Last 15 sessions, 15.3% high to low

Profile

EXEL
52-week range, 90% of the way up
39.7173.69

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

IndexRUI
Employees1077
IPOApr 11, 2000
Beta0.42
ATR, 14d2.21
Rel volume0.36
Short float10.84%
Insider own3.22%
Inst own107.76%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap17.12B
Enterprise Value16.39B
Income885.14M
Sales2.50B
Book/sh7.49
Cash/sh3.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1077
IPOApr 11, 2000

Ratios

P/E21.00
Forward P/E16.75
PEG0.87
P/S6.86
P/B9.36
P/C19.19
P/FCF14.74
EV/EBITDA15.88
EV/Sales6.56
Quick Ratio3.14
Current Ratio3.21
Debt/Eq0.09
LT Debt/Eq0.09
Option/ShortYes / Yes

Earnings

EPS (ttm)3.34
EPS next Y4.19
EPS next Q0.96
EPS this Y20.50%
EPS next Y12.88%
EPS next 5Y19.34%
EPS past 3/5Y70.35% 51.19%
Sales past 3/5Y12.93% 18.63%
EPS Y/Y TTM40.53%
Sales Y/Y TTM9.12%
EPS Q/Q22.71%
Sales Q/Q10.19%
EarningsOct 29 AMC
EPS/Sales Surpr.5.96% 1.88%

Ownership

Insider Own3.22%
Insider Trans-1.76%
Inst Own107.76%
Inst Trans-0.70%
ROA33.17%
ROE44.32%
ROIC44.34%
Gross Margin96.26%
Oper. Margin40.21%
Profit Margin35.45%
SMA204.33%
SMA5013.43%
SMA20034.99%
Trades-

Technical

Shs Outstand244.68M
Shs Float236.15M
Short Float10.84%
Short Ratio10.52
Short Interest25.59M
52W High73.69 -4.80%
52W Low39.71 76.67%
Volatility4.28% 3.23%
ATR (14)2.21
RSI (14)63.78
Beta0.42
Rel Volume0.36
Avg Volume2.43M
Volume182,668

Performance

Perf Week-3.57%
Perf Month17.89%
Perf Quarter38.62%
Perf Half Y36.78%
Perf YTD60.06%
Perf Year63.25%
Perf 3Y234.07%
Perf 5Y293.25%
Perf 10Y327.78%
Recom2.47
Target Price61.57
Prev Close70.58
Price70.16
Change %-0.60%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 19, 2026InitiatedBBMO Capital MarketsMarket Perform$54-23.0%
Aug 06, 2026DowngradeLLeerink PartnersOutperform → Market Perform$52-25.9%
Jun 25, 2026ResumedTTruistHold$54-23.0%
Jan 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$48-31.6%
Jan 05, 2026DowngradeBBofA SecuritiesNeutral → Underperform$41-41.6%
Nov 18, 2025InitiatedWWolfe ResearchPeer Perform
Nov 03, 2025DowngradeGGuggenheimBuy → Neutral
Oct 21, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$48-31.6%
Sep 19, 2025ResumedBBarclaysEqual Weight$40-43.0%
Sep 17, 2025ResumedBBarclaysEqual Weight$40-43.0%

Peers

Mkt cap
TickerCompanyMkt cap
INCYIncyte Corp24.58B
GMABGenmab ADR32.43B
JAZZJazz Pharmaceuticals plc15.74B
ONCBeOne Medicines Ltd ADR44.16B
SMMTSummit Therapeutics Inc13.34B
RVMDRevolution Medicines Inc40.09B
IBRXImmunityBio Inc7.04B
BMRNBiomarin Pharmaceutical Inc11.12B
BMYBristol-Myers Squibb Co125.96B
NBIXNeurocrine Biosciences Inc17.29B

Insider trading

latest 14 of 61
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Beckerle Mary CDirectorAug 10 '26Sale53.669,812526,51216,079Aug 12 07:34 PM
MARY BECKERLEDirectorAug 10 '26Proposed Sale53.669,812526,496Aug 10 04:15 PM
WYSZOMIERSKI JACK LDirectorJun 01 '26Sale50.553,925198,409284,384Jun 03 06:52 PM
Eckhardt Sue GailDirectorJun 01 '26Sale50.149,812491,97416,079Jun 03 06:51 PM
Eckhardt Sue GailDirectorJun 01 '26Proposed Sale50.879,812499,136Jun 01 04:16 PM
JACK L WYSZOMIERSKIDirectorJun 01 '26Proposed Sale50.553,925198,409Jun 01 04:04 PM
Aftab DanaEVP, Research and DevelopmentMay 26 '26Sale50.3543,4512,187,758594,741May 28 06:25 PM
DANA T AFTABOfficerMay 26 '26Proposed Sale50.3543,4512,187,758May 26 04:09 PM
Haley Patrick J.EVP, CommercialMay 20 '26Sale49.8132,1101,599,399357,638May 22 05:01 PM
PATRICK JOSEPH HALEYOfficerMay 20 '26Proposed Sale49.8132,1101,599,444May 20 04:31 PM
Senner Christopher J.EVP and CFOMay 18 '26Sale50.0034,9011,745,050952,317May 19 06:58 PM
Hefti BrendaSVP and General CounselMay 18 '26Sale50.216,625332,641106,762May 19 06:58 PM
CHRISTOPHER J SENNEROfficerMay 18 '26Proposed Sale50.0034,9011,745,179May 18 04:49 PM
BRENDA JOY HEFTIOfficerMay 18 '26Proposed Sale50.216,625332,641May 18 04:23 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XMHQInvesco S&P MidCap Quality ETFAUM: 5.81B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
IBBiShares Biotechnology ETFAUM: 11.36B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B

News

latest 14 of 206
  • Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November (Business Wire)
  • Exelixis Matches The Whisper As Cabometyx Growth Accelerates, But Zanzalintinib Delays And Flat Guidance Temper A Stock Near Its Highs (Earnings Whispers)
  • Exelixis: Q3 Earnings Snapshot (Associated Press)
  • Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
  • Exelixis Rises with Earnings on Tap (FX Empire)
  • Loading…
  • Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance (Earnings Whispers)
  • Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 (Business Wire)
  • Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
  • GameStop Upgraded, Celestica Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
  • Is Exelixis Stock Engineered To Make You Money? (Trefis)
  • Exelixis Shares Rising on CABOMETYX Revenue (FX Empire)
  • EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review William Blair Sees More Swings In Near Term (Stocktwits)
  • Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay (Investor's Business Daily)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-290.9400.8870.850658.7646.5113
2026Q22026-08-050.9100.8530.817628.69636.414
2026Q12026-05-050.8700.7620.787610.81607.5113
2025Q42026-02-100.9400.8300.885598.66596.5215
2025Q32025-11-040.7800.6850.695597.76590.1612
2025Q22025-07-280.7500.6680.650568.26577.199
2025Q12025-05-130.6200.3580.554555.45499.615
2024Q42025-02-110.4800.4260.476566.76564.4319
2024Q32024-10-290.4000.3390.405539.54490.3115
2024Q22024-08-060.7700.3100.769637.18465.4717
2024Q12024-04-300.1200.2230.122425.23461.0416
2023Q42024-02-060.2700.2300.273479.65480.3314
2023Q32023-11-010.0000.0980.003471.92473.4813
2023Q22023-08-010.2500.1540.248469.85446.2910
2023Q12023-05-090.1200.1570.123408.79422.6614
2022Q42023-02-07-0.090-0.108-0.093423.92417.6114

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.0200.9661.019967.78968.24
2020FY0.3500.3160.352987.54988
2021FY0.7200.4780.7171,4351,339
2022FY0.5600.5640.5621,6111,603
2023FY0.6500.6170.6461,8301,832
2024FY1.7601.7311.7602,1692,165
2025FY3.0802.9812.7802,3202,321
2026FY-3.712--2,556
2027FY-4.190--2,882
2028FY-5.235--3,314
2029FY-6.660--3,672
2030FY-5.948--3,477

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-301538658.43638.3687
2026Q4S2026-10-291511663.24640.68701.67
2026Q4S2026-10-201511663.25640.68701.67
2026Q4S2026-10-1615110663.25640.68701.67
2026Q4S2026-10-0915110664.27640.68701.67
2026Q4S2026-10-0716110664.44640.68701.67
2026Q4S2026-10-0516110664.5640.68701.67
2026Q4S2026-10-0216110664.47640.68701.67
2026Q4S2026-09-2916011664.05640.68701.67
2026Q4S2026-09-2816011664.04640.68701.67
2026Q4S2026-09-1017012660.68607701.67
2026Q4S2026-08-2717012660.68607701.67
2026Q4S2026-08-1718013659.64607701.67
2026Q4S2026-08-0717013658.55607701.67

Estimate history

EPS, annual0.492.2061.0190.3520.7170.5620.6461.762.7763.3415
Period201720182019202020212022202320242025TTM
EPS, quarterly0.4050.4760.5540.650.6950.8850.7870.8170.853
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual452.677853.826967.775987.5381434.971611.0621830.2082168.7012320.1262496.86
Period201720182019202020212022202320242025TTM
Sales, quarterly539.542566.755555.447568.261597.755598.663610.812628.69658.696
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual296.209299.876304.831311.627318.842323.951302.793281.732262.483244.678
Period201720182019202020212022202320242025MRQ
Shares, quarterly285.78281.732275.033270.132268.098262.483253.701248.885244.678
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2,496.862,320.132,168.701,830.211,611.061,434.97987.54967.77853.83
Cost of Goods Sold Incl. D&A93.3283.7076.2272.5557.9152.8736.2733.1026.35
Gross Profit2,403.542,236.432,092.491,757.661,553.151,382.10951.27934.68827.48
Selling, General and Administrative Excl. Other1,399.451,343.731,402.541,586.781,351.671,095.43841.21565.21388.62
Research and Development834.63825.00910.411,044.07891.81693.72547.85336.96182.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,004.09892.70689.95170.88201.48286.67110.06369.47438.86
Interest Expense0.000.000.000.000.000.000.000.00-
Unusual Expense0.6920.5185.33--1.20-0.800.00-0.00
Net Income Before Taxes1,065.84941.21681.64257.52234.35294.15130.84398.11452.09
Income Taxes180.70158.64160.3749.7652.0763.0919.0677.10-237.98
Consolidated Net Income885.14782.57521.27207.76182.28231.06111.78321.01690.07
Net Income From Continuing Operations885.14782.57521.27207.76182.28231.06111.78321.01690.07
Net Income885.14782.57521.27207.76182.28231.06111.78321.01690.07
EPS (Recurring)3.462.831.960.650.560.720.351.022.21
EPS (Basic, Before Extraordinaries)3.462.881.800.650.570.730.361.062.32
EPS (Diluted)3.342.781.760.650.560.720.351.022.21
EBITDA1,031.90921.76718.75196.60222.36300.30124.03380.64446.62
Non-Operating Income (Expense)62.4469.0277.0286.6431.676.6920.7828.6413.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense87.2489.2674.1384.0184.9887.4749.5541.3232.09
Price To Earnings Ratio21.1221.1221.2285.5016.9025.5457.4917.298.91
Price To Sales Ratio5.985.294.644.213.234.116.465.547.12
Gross Margin96.2696.3996.4996.0496.4196.3296.3396.5896.91
Operating Margin40.2138.4831.819.3412.5119.9811.1438.1851.40
Net Margin35.4533.7324.0411.3511.3116.1011.3233.1780.82
Shares Outstanding244.68262.48281.73302.79323.95318.84311.63304.83299.88
Market Capitalization17,222.3017,222.309,509.787,460.275,173.885,783.746,226.605,353.775,881.00

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue658.70628.69610.81598.66597.75568.26555.45566.75
Cost of Goods Sold Incl. D&A26.2320.6619.9526.4818.5719.4719.1719.96
Gross Profit632.46608.03590.86572.18579.18548.79536.27546.79
Selling, General and Administrative Excl. Other364.04359.62339.52336.27322.82335.21349.42383.33
Research and Development209.48211.99199.92213.25199.16200.36212.23249.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income268.42248.41251.34235.91256.36213.58186.86163.46
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.6919.820.000.000.25
Net Income Before Taxes282.79262.68267.69252.69252.41230.41205.69184.77
Income Taxes64.6950.6357.228.1658.8445.5746.0744.91
Consolidated Net Income218.09212.05210.47244.53193.58184.85159.62139.86
Net Income From Continuing Operations218.09212.05210.47244.53193.58184.85159.62139.86
Net Income218.09212.05210.47244.53193.58184.85159.62139.86
EPS (Recurring)0.850.820.790.890.740.650.550.48
EPS (Basic, Before Extraordinaries)0.880.850.810.920.720.680.570.49
EPS (Diluted)0.850.820.790.880.690.650.550.48
EBITDA275.36255.40258.29242.86263.78220.92194.20171.10
Non-Operating Income (Expense)14.3614.2616.3517.4715.8716.8418.8321.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense22.6925.7222.9515.8824.4028.5020.4820.81
Price To Earnings Ratio21.1218.0315.4118.4519.8120.0020.8321.22
Price To Sales Ratio5.985.954.945.194.885.894.334.60
Gross Margin96.0296.7196.7395.5896.8996.5796.5596.48
Operating Margin40.7539.5141.1539.4142.8937.5833.6428.84
Net Margin33.1133.7334.4640.8532.3832.5328.7424.68
Shares Outstanding244.68248.88253.70262.48268.10270.13275.03281.73
Market Capitalization17,222.3013,676.2311,138.9211,751.3511,118.0812,019.6110,333.219,509.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,059.091,111.28995.301,308.471,467.071,206.54852.24693.33388.27
Short Term Receivables299.32280.34250.51222.08285.55165.38120.17178.8381.19
Inventories21.6922.3917.3233.3027.4920.9712.899.846.66
Other Current Assets63.2053.5854.8354.9154.6352.5125.8915.028.75
Total Current Assets1,443.291,467.581,317.961,618.761,834.751,445.391,011.19897.02484.87
Net Property, Plant & Equipment258.00291.95361.98345.44149.15110.3990.7356.7625.74
Total Investments and Advances603.60637.29728.72758.21387.83332.31536.38158.2968.90
Long-Term Note Receivable0.000.371.321.661.67----
Intangible Assets63.6863.6863.6863.6863.6863.6863.6863.6863.68
Deferred Tax Assets330.19459.31415.19231.11111.66166.88181.62245.39-
Other Assets183.2766.78107.5652.6367.4928.8411.312.4212.09
Total Assets2,882.032,986.982,996.403,071.492,616.242,147.501,894.911,423.57655.29
Short Term Debt Incl. Current Port. of LT Debt27.8825.0125.7117.665.143.022.732.790.00
Accounts Payable29.6238.1933.7732.6724.2623.6311.5810.909.57
Other Current Liabilities348.14340.57334.79274.03308.19178.00128.4491.78105.59
Total Current Liabilities405.64403.77394.28324.36337.59204.66142.75105.47115.17
Long Term Debt173.04190.82189.94190.1751.2749.0948.0112.260.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities37.6139.2954.05--10.179.241.28-
Other Liabilities104.42108.8994.2268.5316.764.488.9417.10255.16
Total Liabilities720.71742.77732.49583.06405.62268.39208.94136.11370.33
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2,161.322,244.202,263.912,488.432,210.611,879.111,685.971,287.45284.96
Total Shareholders Equity2,161.322,244.202,263.912,488.432,210.611,879.111,685.971,287.45284.96
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2,161.322,244.202,263.912,488.432,210.611,879.111,685.971,287.45284.96
Total Liabilities & Stockholders Equity2,882.032,986.982,996.403,071.492,616.242,147.501,894.911,423.57655.29
Book Value Per Share8.237.977.487.686.936.035.534.290.96
Tangible Book Value Per Share7.997.747.277.486.735.835.324.080.75
Full-Time Employees1,0771,1471,3101,223954773617484372
Price to Book Ratio9.424.183.182.082.643.333.194.5837.66
Return on Assets26.6717.426.856.419.705.5319.3566.3924.56
Return on Equity35.5323.138.747.7611.306.2721.5987.7782.22
Return on Invested Capital33.5221.418.476.8110.225.8018.5153.0953.99
Quick Ratio3.503.583.304.895.356.966.998.414.15
Current Ratio3.563.633.344.995.437.067.088.504.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income885.14782.57521.27207.76182.28231.06111.78321.01690.07
Depreciation27.8129.0528.8025.7220.8818.9613.9711.177.77
Other Funds (Non Cash)143.95137.60222.81247.02232.61143.26108.1156.6941.76
Funds from Operations1,183.141,075.46713.42347.30375.41439.82249.12459.87495.48
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.08-191.20-13.45-13.97-12.80-39.01-40.1467.08-79.76
Cash from Operating Activities1,173.06884.27699.97333.32362.61400.80208.98526.96415.72
Capital Expenditures-11.97-8.43-28.43-40.47-27.71-64.22-30.34-12.83-33.30
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.31
Purchase or Sale of Investments89.46390.37-50.60136.01-385.9621.34-100.87-574.41-264.86
Purchase of Investments-682.52-632.50-927.90-902.47-1,450.72-1,357.17-1,070.27-1,182.68-557.83
Sale Or Maturity of Investments771.991,022.87877.311,038.481,064.761,378.51969.40608.27292.97
Other Uses-16.60-31.50-37.75-122.50-110.750.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities60.89350.44-116.78-26.95-524.41-42.88-131.22-587.25-297.85
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-1,226.72-898.37-590.18-516.9323.8924.3124.8922.5017.28
Repurchase of Common Pref Stock-1,260.91-947.51-652.03-550.380.000.000.000.000.00
Sale of Common Pref Stock34.1949.1461.8533.4523.8924.3124.8922.5017.28
Proceedsfrom Stock Options0.000.000.0033.450.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-0.01
Change in Long Term Debt0.000.000.000.000.000.000.000.00-0.01
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-0.01
Net Financing Active Other Cash Flow-78.76-71.22-38.62-29.12-23.30-39.11-50.02-9.95-7.57
Other Financing Activities Uses-78.76-71.22-38.62-29.12-23.30-39.11-50.02-9.95-7.57
Cash from Financing Activities-1,305.48-969.59-628.81-546.050.59-14.80-25.1312.559.69
Net Change in Cash-71.53265.11-45.62-239.68-161.21343.1252.63-47.74127.56
Free Cash Flow1,161.09875.84671.54292.86334.91336.58178.64514.12382.42
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow12.8614.0214.9826.3315.5417.5135.7310.4215.90
Deferred Taxes & Investment Tax Credit-126.24-59.46-133.21-60.3646.5315.2771.00-244.11

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments892.02839.38777.211,059.09988.53791.10
Short Term Receivables338.27334.61339.45299.32321.12306.25
Inventories29.8728.7326.6121.6927.4023.48
Other Current Assets61.4748.0965.3863.2065.1959.93
Total Current Assets1,321.621,250.821,208.641,443.291,402.261,180.76
Net Property, Plant & Equipment87.2892.6795.52258.00104.75110.31
Total Investments and Advances507.76544.93649.14603.60578.29594.65
Intangible Assets63.6863.6863.6863.6863.6863.68
Deferred Tax Assets295.56294.20293.73330.19418.58419.24
Other Assets237.59247.93282.87183.27254.42307.90
Total Assets2,513.492,494.232,593.592,882.032,823.552,678.08
Short Term Debt Incl. Current Port. of LT Debt0.000.000.0027.880.000.00
Accounts Payable30.8339.0624.1529.6225.3525.82
Other Current Liabilities381.04322.87346.82348.14348.43310.29
Total Current Liabilities411.88361.93370.98405.64373.78336.11
Long Term Debt162.20165.93169.54173.04176.46179.84
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---37.61--
Other Liabilities105.58122.62117.33104.42112.61128.59
Total Liabilities679.66650.47657.85720.71662.85644.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,833.831,843.761,935.752,161.322,160.702,033.54
Total Shareholders Equity1,833.831,843.761,935.752,161.322,160.702,033.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,833.831,843.761,935.752,161.322,160.702,033.54
Total Liabilities & Stockholders Equity2,513.492,494.232,593.592,882.032,823.552,678.08
Book Value Per Share7.497.417.638.238.067.53
Tangible Book Value Per Share7.237.157.387.997.827.29
Full-Time Employees---1,077--
Price to Book Ratio9.427.135.215.445.495.69
Return on Assets33.1733.2830.6926.6723.4422.10
Return on Equity44.3244.3940.9935.5330.5629.00
Return on Invested Capital10.9310.5510.0010.488.288.35
Quick Ratio3.143.383.193.503.683.44
Current Ratio3.213.463.263.563.753.51

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income218.09212.05210.47244.53193.58184.85
Depreciation6.936.986.956.957.427.34
Other Funds (Non Cash)34.3445.7935.0528.7744.5337.06
Funds from Operations259.37264.82252.47406.48245.53229.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital20.5842.92-0.62-72.9644.79-180.26
Cash from Operating Activities279.96307.74251.84333.51290.3248.99
Capital Expenditures-2.49-6.82-1.51-1.16-1.48-2.84
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments3.36100.75-49.0434.4032.14251.62
Purchase of Investments-184.90-68.52-274.16-154.94-189.37-101.48
Sale Or Maturity of Investments188.25169.27225.12189.34221.51353.10
Other Uses-7.58-2.50-0.53-6.00-5.25-0.75
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-6.7191.43-51.0727.2425.41248.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-246.56-307.53-422.88-249.74-100.48-275.84
Repurchase of Common Pref Stock-249.96-322.97-430.35-257.62-104.03-301.92
Sale of Common Pref Stock3.4015.447.477.883.5526.08
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-3.36-36.34-34.23-4.83-3.38-40.50
Other Financing Activities Uses-3.36-36.34-34.23-4.83-3.38-40.50
Cash from Financing Activities-249.92-343.88-457.11-254.57-103.86-316.34
Net Change in Cash23.3355.30-256.34106.19211.87-19.32
Free Cash Flow277.47300.93250.34332.36288.8446.16
Price to Free Cash Flow12.8612.3712.7813.7514.3217.41

Revenue breakdown

License2024: 349.24M 2025: 214.38M
Product, Gross2024: 2.52B 2025: 3.01B
Product, Sales Discounts And Allowances2024: -708.85M 2025: -889.00M
Service2024: 10.06M 2025: -17.05M
Europe2024: 318.63M 2025: 154.17M
Japan2024: 27.08M 2025: 25.59M
United States2024: 1.82B 2025: 2.14B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.84%25.6M236.2M2.39M
2026-10-1511.39%27.3M239.8M2.37M
2026-09-3011.75%28.2M239.9M2.37M
2026-09-1511.00%26.4M239.9M2.55M
2026-08-3111.94%28.7M239.9M2.56M
2026-08-1411.68%28.0M239.9M2.64M
2026-07-3111.99%28.7M239.9M2.68M
2026-07-1512.70%30.9M243.3M2.73M
2026-06-3011.73%28.5M243.3M2.67M
2026-06-1512.62%30.6M242.8M2.54M
2026-05-2912.20%29.7M243.4M2.76M
2026-05-1512.43%30.3M243.5M2.82M
2026-04-3012.37%30.0M242.6M2.74M
2026-04-1511.54%28.3M245.2M2.74M
2026-03-3110.86%27.3M251.1M2.81M
2026-03-1310.50%26.4M251.1M2.79M
2026-02-2710.48%26.3M251.1M2.62M
2026-02-1311.47%28.8M251.1M2.58M
2026-01-3010.79%27.9M258.3M2.62M
2026-01-159.95%25.8M258.9M2.79M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.0043.0047.1037.005.4892.000.000.971-0.1680.007
call30.0038.0042.100.004.6300.000.000.966-0.1650.008
call34.0034.4038.1024.904.0500.000.000.960-0.1620.009
call35.0033.2037.100.003.9160.000.000.959-0.1610.010
call36.0032.2036.1026.733.7863000.000.957-0.1600.010
call37.0031.9035.1014.003.6603.000.000.956-0.1590.010
call38.0030.0034.100.003.5370.000.000.954-0.1580.011
call39.0029.2033.1013.203.41810.000.000.952-0.1570.011
call40.0028.2032.1032.163.3014.000.000.951-0.1560.011
call41.0027.2031.1021.753.18746.000.000.949-0.1550.012
call42.0026.1030.1013.003.0764.000.000.947-0.1540.012
call43.0025.1029.1020.022.96750.000.000.945-0.1530.012
call44.0024.5027.909.002.75931.000.000.943-0.1510.013
call45.0023.1027.2011.602.8302210.000.968-0.0770.008
call46.0022.1026.209.522.70210.000.000.938-0.1490.014
call47.0021.0025.2024.552.6001.000.000.936-0.1470.014
call48.0020.2024.207.932.5233000.000.964-0.0750.009
call49.0019.4023.205.012.42552.000.000.930-0.1440.015
call50.0018.4022.2018.202.3691910.000.960-0.0730.009
call55.0013.4017.2015.601.8432970.000.908-0.1320.018
call57.5010.6014.700.001.6200.000.000.895-0.1260.020
call60.008.9012.2010.941.4016840.000.878-0.1180.022
call62.506.009.809.991.2251.000.000.853-0.1090.025
call65.004.207.405.901.0152,2930.000.797-0.1130.031
call67.503.103.703.200.47955111.000.669-0.1480.040
call70.001.352.401.300.5211,3882.000.531-0.1230.044
call72.500.002.601.180.81649.000.000.423-0.1970.043
call75.000.250.500.350.5471,5061.000.262-0.1230.036
call77.500.001.000.000.6960.000.000.197-0.1190.031
call80.000.000.750.250.8031380.000.168-0.1240.028
call85.000.001.600.171.0365.000.000.138-0.1400.024
put25.000.001.150.003.4580.000.00-0.015-0.0800.004
put30.000.000.750.002.8930.000.00-0.018-0.0790.005
put34.000.000.950.902.5072.000.00-0.021-0.0770.006
put35.000.001.551.802.4171.000.00-0.022-0.0770.006
put36.000.001.902.752.8313040.00-0.043-0.1560.010
put37.000.002.151.552.7779.000.00-0.046-0.1640.011
put38.000.001.250.452.1631.000.00-0.025-0.0760.006
put39.000.000.952.352.0831.000.00-0.025-0.0750.007
put40.000.000.951.402.0042.000.00-0.026-0.0750.007
put41.000.001.151.331.92823.000.00-0.027-0.0740.007
put42.000.001.151.401.8522.000.00-0.029-0.0730.007
put43.000.000.752.001.8991.000.00-0.037-0.0940.009
put44.000.001.151.251.70713.000.00-0.031-0.0720.008
put45.000.001.150.091.63796.000.00-0.032-0.0710.008
put46.000.001.150.351.5675.000.00-0.034-0.0710.008
put47.000.000.951.101.49753.000.00-0.035-0.0700.009
put48.000.000.750.651.5353410.00-0.046-0.0890.011
put49.000.001.150.851.3658.000.00-0.038-0.0690.009
put50.000.000.750.051.3023,2380.00-0.040-0.0680.009
put55.000.001.150.201.2606260.00-0.092-0.1260.018
put57.500.002.150.750.8441,5010.00-0.059-0.0600.013
put60.000.002.200.140.6983880.00-0.070-0.0570.015
put62.500.001.500.300.5555060.00-0.086-0.0520.017
put65.000.100.300.300.56891.001.00-0.203-0.1060.031
put67.500.002.800.600.71617.000.00-0.334-0.1400.040
put70.001.351.951.400.46646.000.00-0.469-0.1160.044
put72.501.254.902.400.8137.000.00-0.579-0.1810.043
put75.003.207.100.000.9420.000.00-0.738-0.1150.036
put77.505.509.300.001.0270.000.00-0.803-0.1100.031
put80.007.9012.100.001.2710.000.00-0.833-0.1150.028
put85.0012.9017.000.001.5210.000.00-0.862-0.1310.024

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13GSEC
2026-11-09SCHEDULE 13D/ASEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-10-02SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-14SCHEDULE 13D/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-07-03SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-298-KCurrent report2026-05-26SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-26144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800526.51K1
2026-070000
2026-0600690.38K2
2026-05009.93M7
2026-040000
2026-030000
2026-020020.60M11
2026-010000
2025-120000
2025-111.19M110.49M6

Institutional holders

Manager% owned
BlackRock, Inc.11.57%
FARALLON CAPITAL MANAGEMENT, L.L.C.5.36%
RENAISSANCE TECHNOLOGIES LLC5.34%
VANGUARD PORTFOLIO MANAGEMENT LLC4.79%
AQR CAPITAL MANAGEMENT LLC4.39%
VANGUARD CAPITAL MANAGEMENT LLC4.36%
STATE STREET CORP3.97%
FULLER & THALER ASSET MANAGEMENT, INC.3.55%
GEODE CAPITAL MANAGEMENT, LLC3.33%
LSV ASSET MANAGEMENT3.18%

Funds

Fund% owned
iShares Core S&P Mid-Cap ETF3.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
FULLERTHALER BEHAVIORAL SMALL CAP EQUITY2.80%
VANGUARD SMALL-CAP INDEX FUND2.18%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.26%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Invesco S&P MidCap Quality ETF1.10%
State Street SPDR S&P MidCap 400SM ETF Trust0.77%
State Street(R) SPDR(R) S&P(R) Biotech ETF0.75%
iShares Biotechnology ETF0.69%

OakChart. EXEL. Cached 15 minutes.